HKSE · 1652.HK
Fusen Pharmaceutical Company Limited
HK$1.03+HK$0.03 (+3.0%)
Fusen Pharmaceutical Company Limited’s quoted price sits in the lower half of its reported 52-week range, 28.47% below the high.
Loading market information…
HKSE · 2563.HK · HKD
Stock price
Quote as of Oct 30, 2026, 05:07 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Beijing Biostar Pharms Co Ltd’s quoted price sits in the lower half of its reported 52-week range, 35.24% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Beijing Biostar Pharmaceuticals Co. Ltd. primarily focuses on developing innovative therapies for tumors. The company is dedicated to creating novel anti-cancer drugs, each secured by independent intellectual property rights. A prominent product in its portfolio is the Utidelone injection, a next-generation microtubule inhibitor produced through a unique microbial fermentation process. This enterprise was co-founded by Li Tang and Rong Guo Qiu on July 11, 2002, and operates from its headquarters in Beijing, China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:57 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$1.03+HK$0.03 (+3.0%)
Fusen Pharmaceutical Company Limited’s quoted price sits in the lower half of its reported 52-week range, 28.47% below the high.
HK$2.37-HK$0.12 (-4.63%)
Pak Fah Yeow International Limited’s quoted price sits in the lower half of its reported 52-week range, 13.19% below the high.
HK$1.74+HK$0.06 (+3.57%)
Guangdong Kanghua Healthcare Group Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 23.68% below the high.
HK$0.47-HK$0.02 (-4.08%)
China Biotech Services Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 54.81% below the high.
HK$0.06-HK$0.00 (-1.54%)
Uni-Bio Science Group Limited’s quoted price sits in the lower half of its reported 52-week range, 61.9% below the high.
HK$1.39+HK$0.01 (+0.72%)
Suzhou Basecare Medical Corporation Limited’s quoted price sits in the lower half of its reported 52-week range, 47.55% below the high.
HK$0.62-HK$0.03 (-3.88%)
Yunkang Group Limited’s quoted price sits in the lower half of its reported 52-week range, 50.4% below the high.
HK$0.40HK$0.00 (0.0%)
ClouDr Group Limited’s quoted price sits in the lower half of its reported 52-week range, 68.75% below the high.
